SECOND EXTENSION - GRANTED
granted
on 25 Jun 2024
Last Applicant/ Owned by
201 Tresser Boulevard
Stamford
CT
06901
Serial Number
97009389 filed on 02th Sep 2021
Registration Number
N/A
Correspondent Address
Fara S. Sunderji
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
KNOA PHARMA
Pharmaceutical research and development A house mark for a full line of pharmaceuticals; pharmaceuticals for use in the treatment of central nervous system disorders, pain, opioid overdose, opioid reversal, opioid use disorders, interstitial cystitis/bladder pain syndrome (IC/BPS), Overactive Bladder (OAB), Alcohol Use Disorder, Substance Use Disorder, sleep disorders including Insomnia Associate Read More
Classification Information
Class [042]
Computer & Software Services & Scientific Services
Pharmaceutical research and development
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [005]
Pharmaceutical Products
A house mark for a full line of pharmaceuticals; pharmaceuticals for use in the treatment of central nervous system disorders, pain, opioid overdose, opioid reversal, opioid use disorders, interstitial cystitis/bladder pain syndrome (IC/BPS), Overactive Bladder (OAB), Alcohol Use Disorder, Substance Use Disorder, sleep disorders including Insomnia Associated with Alcohol Cessation (IAAC), anaphylaxis; pharmaceuticals for use in the treatment of oncology conditions, specifically glioblastoma multiforme (GBM), non Hodgkin lymphoma, solid tumors, melanoma, chronic myelogenous leukemia, hemato-oncology, refractory/relapsed malignancies, alone or in combination with other agents; analgesics; pharmaceuticals, namely, opioid antagonists; syringes filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; syringes filled with opioid antagonists; injectors filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; injectors filled with opioid antagonists; injectable pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; injectable pharmaceuticals, namely, opioid antagonists
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 97009389
Mark Type
No Service Mark
Attorney Docket Number
No 491396-00002
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 13th Dec 2024 | SOU TEAS EXTENSION RECEIVED |
| 25th Jun 2024 | SOU EXTENSION 2 GRANTED |
| 25th Jun 2024 | SOU EXTENSION 2 FILED |
| 25th Jun 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 25th Jun 2024 | SOU TEAS EXTENSION RECEIVED |
| 21st Dec 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 19th Dec 2023 | SOU EXTENSION 1 GRANTED |
| 19th Dec 2023 | SOU EXTENSION 1 FILED |
| 19th Dec 2023 | SOU TEAS EXTENSION RECEIVED |
| 27th Jun 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |